| Autor: |
Ming-Lun Yeh, Po-Cheng Liang, Sam Trinh, Ching-I Huang, Chung-Feng Huang, Ming-Yen Hsieh, Jee-Fu Huang, Chia-Yen Dai, Wan-Long Chuang, Mindie H. Nguyen, Ming-Lung Yu |
| Jazyk: |
angličtina |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
Journal of the Formosan Medical Association, Vol 121, Iss 7, Pp 1273-1282 (2022) |
| Druh dokumentu: |
article |
| ISSN: |
0929-6646 |
| DOI: |
10.1016/j.jfma.2021.09.009 |
| Popis: |
Background/Purpose: Switching to a tenofovir alafenamide (TAF)-containing regimen has been reported to be associated with body weight gain in human immunodeficiency virus-infected subjects. We aimed to investigate the body weight change and virological, hepatic, and renal outcomes of TAF switching among chronic hepatitis B (CHB) patients. Methods: This retrospective study included 121 CHB patients who were switched to TAF after >12 months of treatment with another nucleot(s)ide analog (NUC). All patients were monitored for 12 months. Results: The cohort was mostly Asian (96.7%) with a mean age of 55 years, 72% male, 14% cirrhosis, 21% HBeAg positive, and 75% with prior use of tenofovir disoproxil fumarate. At 12 months after TAF switching, their body weight significantly increased from 66.4 ± 11.8 to 67.8 ± 12.3 kg (p |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
